BioMark Diagnostics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMKDF research report →
About the company
BioMark Diagnostics Inc. is an oncology-focused firm that develops sophisticated diagnostic tools for cancer. These solutions are designed to aid in the identification of the disease, its ongoing monitoring, and the assessment of initial therapeutic interventions.
- CEO
- Rashid Ahmed Maula Bux
- IPO
- 2015
- Employees
- 9
- HQ
- Richmond, BC, CA
Price Chart
- Market Cap
- $40.18M
- P/E
- -33.39
- P/S
- 618.37
- P/B
- 111.70
- EV/EBITDA
- -44.16
- Div Yield
- 0.00%
- Gross Margin
- -147.92%
- Op Margin
- -2073.23%
- Net Margin
- -1852.06%
- ROE
- -153.00%
- ROIC
- -145.19%
- Revenue
- $154.22K · -5.52%
- Net Income
- $-1,927,280 · -35.02%
- EPS
- $-0.02 · -19.76%
- Op Income
- $-1,908,137
- FCF YoY
- -11.12%
- 52W High
- $0.50
- 52W Low
- $0.21
- 50D MA
- $0.42
- 200D MA
- $0.36
- Beta
- -0.25
- Avg Volume
- 1.11K
Get TickerSpark's AI analysis on BMKDF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BMKDF coverage
Recent articles, reports, and earnings notes.
No research on BMKDF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BMKDF report →Similar companies
Peers in the same neighborhood.